Every material Form 8-K Embecta Corp. has filed with the SEC since May 05, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Embecta reported fiscal third-quarter 2026 revenue of $271.7 million, down 8.1% from $295.5 million a year earlier, and net income of $21.1 million, or $0.36 per diluted share, versus $0.78 a year earlier. The company reaffirmed its fiscal 2026 revenue guidance of $1,015 million to $1,035 million and raised its adjusted earnings per share guidance to $1.80 to $1.90 from $1.55 to $1.75.
Q3 revenue $271.7 million, down 8.1%; U.S. revenue down 24.6%, International up 11.5% (reported basis)
Q3 GAAP operating income $48.7 million vs. $94.0 million a year earlier; adjusted operating income $69.4 million vs. $109.1 million
Fiscal 2026 adjusted EPS guidance raised to $1.80-$1.90 from $1.55-$1.75; adjusted operating margin guidance raised to 23.50%-24.00%
Quarterly dividend of $0.01 per share declared, payable September 15, 2026 to holders of record on August 27, 2026
Embecta Corp. completed its acquisition of Owen Mumford Holdings Limited, a privately held UK maker of medical devices and drug-delivery technologies, on May 15, 2026. The company says the deal accelerates its shift into a broad-based medical supplies business and adds the Aidaptus next-generation auto-injector platform. The filing does not disclose Owen Mumford's financial results, and the required financial statements and pro forma information will be filed later by amendment.
Upfront cash payment of £100 million at closing, subject to customary adjustments including closing net cash.
Up to an additional £50 million payable on certain commercial milestones for Aidaptus sales through June 30, 2029.
Transaction completed May 15, 2026 under a Purchase Agreement dated March 19, 2026, with sellers including Mark Owen and Adam Mumford.
Financial statements and pro forma information to be filed by amendment within 71 calendar days of the Item 2.01 filing deadline.
Embecta reported fiscal second-quarter 2026 revenue of $221.8 million, down 14.4%, and a GAAP net loss of $4.1 million, compared with net income of $23.5 million a year earlier. The company lowered its fiscal 2026 guidance, cut its quarterly dividend from $0.15 to $0.01 per share, and authorized a three-year share repurchase program of up to $100 million, while it awaits closing of the Owen Mumford acquisition expected in May 2026.
Q2 U.S. revenues fell 29.4% to $95.4 million; International revenues rose 2.1% to $126.4 million on a reported basis.
Fiscal 2026 reported revenue guidance is now $1,015 million to $1,035 million, down from $1,071 million to $1,093 million.
Fiscal 2026 adjusted earnings per diluted share guidance is now $1.55 to $1.75, down from $2.80 to $3.00.
Quarterly dividend reduced from $0.15 to $0.01 per share, payable June 15, 2026; the Board authorized up to $100 million in buybacks over three years.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Embecta Corp. filing is on SEC EDGAR ↗. 8-K briefs of other companies →